Ananda Pharma Doses First Patient in Phase 2 CIPN Trial
UNITED KINGDOM, June 17, 2026 Ananda Pharma Limited has announced that the first patient has been dosed in the...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
UNITED KINGDOM, June 17, 2026 Ananda Pharma Limited has announced that the first patient has been dosed in the...
SAN ANTONIO, Texas, July 14, 2026 Valion Bio, Inc. has announced major strategic progress across its Entolimod platform, advancing...
NEW YORK, United States – May 5, 2026 Hoth Therapeutics, Inc. has announced that it secured regulatory authorization in...
Alpharetta, Georgia, U.S. | April 15, 2026 Dogwood Therapeutics has announced a major regulatory milestone with the U.S. Food...
